December 9, 2020
Briefing Memorandum for the COVID-19 Advisory Board for President-elect Joseph R. Biden and Vice President-elect Kamala Harris.
From: Jeremy Samuel Faust MD, MS
Brigham and Women’s Hospital Department of Emergency Medicine,
Division of Health Policy and Public Health, Instructor, Harvard Medical School.
Alister F. Martin, MD, MPP
Massachusetts General Hospital Department of Emergency Medicine, Instructor, Harvard Medical School.
Michael Barnett, MD, MS
Assistant Professor, Health Policy and Management,
Harvard T. H. Chan School of Public Health
Max Jordan Nguemeni Tiako, MS
Yale School of Medicine
Sarah E. Wakeman, MD
Medical Director, Mass General Hospital Substance Use Disorder Initiative
Associate Professor of Medicine, Harvard Medical School
Re: Young adult deaths due to COVID-19 and unintentional overdose during the pandemic.
Dear Members of the COVID-19 Advisory Board for the Biden-Harris Transition,
Introduction
This memorandum describes the impact of the COVID-19 pandemic on young adults ages 25-44 in the United States due to coronavirus disease and unintentional overdoses.
Herein, we suggest that the X-waiver requirement for prescribing buprenorphine to treat opioid use disorder be immediately removed during the national emergency in order to increase access to life-saving medication and therefore to decrease the number of unintentional overdose deaths.
Epidemiology
As of December 7, 2020, the novel Coronavirus Disease 2019 (COVID-19) has caused over 282,000 deaths among our fellow Americans this year. While the majority of these deaths have occurred in older persons, the demographic with the largest sustained relative increase in all-cause mortality during the pandemic period has in fact been recorded among adults ages 25-44.[1] [2] COVID-19 has now killed more Americans under the age of 40 (4,674 deaths) than perished during the second Iraq War (4,431 deaths) and in a much shorter period of time.[3] [4] Black and Latinx persons account not merely for a disproportionate fraction of COVID-19 deaths, but an actual majority of COVID-19 deaths among US adults ages 25-44, combining for nearly 79% of all deaths in this age bracket.[5]
Emerging data suggests that overdose deaths have increased during the pandemic period as well, exceeding prior trendsand likely contributing to measurable increases in all-cause excess mortality among young adults in the United States.[6]While some states like Massachusetts have reported no such changes, our own preliminary analysis indicates that among some groups, such as the Black population in Massachusetts, overdose rates appear to have increased during the pandemic.[7] This aligns with observations that Black people with opioid use disorder are at higher risk of COVID-19 mortality and that the opioid epidemic continues to worsen among minoritized populations in particular.[8] [9]
Background: the X-waiver for Buprenorphine
Buprenorphine has been found to be safe and effective in the treatment of opioid use disorders.[10] It helps patients stay in treatment longer, decreases the risk of death, improves social functioning, and lowers healthcare costs.[11] [12] [13][14]
A clause in the 1914 Harrison Narcotics Tax Act first made it illegal for doctors to prescribe a drug to treat addiction.[15]One century later, this decision serves as the foundation for policy in which medications for addiction treatment, like buprenorphine, are substantially restricted for the treatment of addiction (and yet the drug can be prescribed for pain with little oversight).
In 2002, Congress updated this policy under the Drug Addiction Treatment Act of 2000.[16] Its intent was to allow the heavily regulated prescribing of buprenorphine for treatment of opioid use disorder by mandating that healthcare providers first obtain an “X-waiver” by meeting strict requirements. Ironically, these hurdles make it more difficult for care providers to prescribe a medication that reduces deaths from opioids than it is to prescribe the very medications that are in-part responsible for the epidemic in the first place.
The X-waiver requirement was well-intended as it aimed to reduce potential diversion of a controlled substance. It has now outlived its use.[17] Obtaining the X-waiver requires completing an eight-hour training course related to buprenorphine administration and overcoming the administrative hurdles of submitting a certificate of completion and requesting a waiver from the Drug Enforcement Agency (DEA). Today, fewer than 4% of our nation's physicians have an X-waiver to prescribe buprenorphine and more than half of all rural counties lack a buprenorphine prescriber.[18] [19]Subsequently, four out of five patients with opioid use disorder do not currently have access to treatment with buprenorphine. In the midst of the COVID-19 pandemic, which has exacerbated the opioid crisis, the burdens imposed by the X-waiver requirement are causing more harm than good.[20] In fact, forthcoming research indicates a 25% drop in the rate of patients initiating buprenorphine therapy during the pandemic period, a figure which likely represents a conservative estimate.[21] Recent evidence also finds a decrease in substance use-related visits during the partial re-opening phase in Massachusetts among Black and Hispanic patients.[22]
These changes are likely to further exacerbate inequity in buprenorphine availability to non-White populations.[23]Removing the X-waiver requirement would create more opportunities for intervention, including during emergency department care, in-patient hospitalizations, and primary care visits.[24]
Policy recommendation
Access to healthcare has changed during the pandemic period. As above, we are concerned that fewer patients with opioid use disorder are being referred to, enrolled in, and maintained in programs which adhere to gold standard treatment regimens.
Action item: We urge the incoming administration and/or Congress to suspend the X-waiver requirement during the COVID-19 emergency, and to consider removing it permanently.
The legality of executive action on this will need to be determined. Alternatively, an act of Congress to amend DATA 2000, would be legally straightforward, if the political will exists. The action we recommend has already been proposed in bipartisan Congressional legislation.[25]
The United States would not be the first nation to take the approach we suggest. In 1995, France deregulated buprenorphine allowing doctors to freely prescribe it for the treatment of addiction and within 3 years, the number of opioid overdose deaths declined by 79%.[26] A similar drop in the U.S. could have meant 40,000 fewer deaths from opioid overdoses in 2019 alone.[27]
Conclusion
We believe that the COVID-19 pandemic has exacerbated the opioid epidemic in the United States, and that this effect may be magnified in the coming months. With your leadership, the throes of one crisis can be harnessed to ameliorate another. Removing the X-waiver requirement during the pandemic emergency, leading to the consideration of its permanent removal, will save many young lives. This action is evidence-based and safe.
Please do not hesitate to call upon any of us to help study this further or implement the proposed strategy.
The opportunity to save so many lives in a brief interval of time by the correct utilization of our phenomenal national resources and ingenuity is an unusual circumstance. We are honored that you would consider this proposal, which is:
Most respectfully submitted.
Contact: Jeremy Samuel Faust MD, MS 28
[1] Lauren M. Rossen, ‘Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020’, MMWR. Morbidity and Mortality Weekly Report, 69 (2020) <https://doi.org/10.15585/mmwr.mm6942e2>.
[2] Jeremy Samuel Faust and others, Mortality among Adults Ages 25-44 in the United States During the COVID-19 Pandemic(Epidemiology, 25 October 2020) <https://doi.org/10.1101/2020.10.21.20217174>.
[3] Open Calgary, ‘Provisional COVID-19 Deaths Counts by Age in Years | Data | Centers for Disease Control and Prevention’ <https://data.cdc.gov/NCHS/Provisional-COVID-19-Deaths-Counts-by-Age-in-Years/3apk-4u4f> [accessed 8 December 2020].
[4] Department of Defense, ‘CASUALTY STATUS’.
[5] Open Calgary, ‘Monthly Provisional Counts of Deaths by Age Group, Sex, and Race/Ethnicity for Select Causes of Death | Data | Centers for Disease Control and Prevention’ <https://data.cdc.gov/NCHS/Monthly-provisional-counts-of-deaths-by-age-group-/65mz-jvh5> [accessed 8 December 2020].
[6] Joseph Friedman, Leo Beletsky, and David L. Schriger, ‘Overdose-Related Cardiac Arrests Observed by Emergency Medical Services During the US COVID-19 Epidemic’, JAMA Psychiatry, 2020 <https://doi.org/10.1001/jamapsychiatry.2020.4218>.
[7] Massachusetts Department of Health, ‘Current Opioid Statistics | Mass.Gov’ <https://www.mass.gov/lists/current-opioid-statistics#updated-data-%E2%80%93-as-of-november-2020-> [accessed 8 December 2020].
[8] Quan Qiu Wang and others, ‘COVID-19 Risk and Outcomes in Patients with Substance Use Disorders: Analyses from Electronic Health Records in the United States’, Molecular Psychiatry, 2020, 1–10 <https://doi.org/10.1038/s41380-020-00880-7>.
[9] Substance Abuse and Mental Health Service Administration (SAMHSA), ‘Double Jeopardy: COVID-19 and Behavioral Health Disparities for Black and Latino Communities in the U.S. (Submitted by OBHE)’, 5.
[10] Paul J. Fudala and others, ‘Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone’, The New England Journal of Medicine, 349.10 (2003), 949–58 <https://doi.org/10.1056/NEJMoa022164>.
[11] Richard P. Mattick and others, ‘Buprenorphine Maintenance versus Placebo or Methadone Maintenance for Opioid Dependence’, The Cochrane Database of Systematic Reviews, 2, 2014, CD002207 <https://doi.org/10.1002/14651858.CD002207.pub4>.
[12] Luis Sordo and others, ‘Mortality Risk during and after Opioid Substitution Treatment: Systematic Review and Meta-Analysis of Cohort Studies’, BMJ, 357 (2017), j1550 <https://doi.org/10.1136/bmj.j1550>.
[13] Johan Kakko and others, ‘1-Year Retention and Social Function after Buprenorphine-Assisted Relapse Prevention Treatment for Heroin Dependence in Sweden: A Randomised, Placebo-Controlled Trial’, Lancet (London, England), 361.9358 (2003), 662–68 <https://doi.org/10.1016/S0140-6736(03)12600-1>.
[14] J.B. Kessel, Liana Bruce, and D.A. Nemecek, ‘Clinical and Cost Outcomes of Buprenorphine Treatment in a Commercial Benefit Plan Population’, American Journal of Pharmacy Benefits, 10 (2018), 84–89.
[15] Jeremy Lesser, ‘Today Is the 100th Anniversary of the Harrison Narcotics Tax Act’, Drug Policy Alliance<https://drugpolicy.org/blog/today-100th-anniversary-harrison-narcotics-tax-act> [accessed 8 December 2020].
[16] Tom Bliley, ‘H.R.2634 - 106th Congress (1999-2000): Drug Addiction Treatment Act of 2000’, 2000, 1999/2000 <https://www.congress.gov/bill/106th-congress/house-bill/2634> [accessed 8 December 2020].
[17] Faust, ‘Cut the Federal Bureaucratic Sludge - The Boston Globe’ <https://www.bostonglobe.com/opinion/2019/10/08/cut-federal-bureaucratic-sludge/JsLjUUdmy2WwA6xdQXjoGI/story.html> [accessed 8 December 2020].
[18] Rebecca L. Haffajee, Amy S.B. Bohnert, and Pooja A. Lagisetty, ‘Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment’, American Journal of Preventive Medicine, 54.6 Suppl 3 (2018), S230–42 <https://doi.org/10.1016/j.amepre.2017.12.022>.
[19] C. Holly A. Andrilla and others, ‘Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update’, The Journal of Rural Health, 35.1 (2019), 108–12 <https://doi.org/10.1111/jrh.12307>.
[20] Danielle F. Haley and Richard Saitz, ‘The Opioid Epidemic During the COVID-19 Pandemic’, JAMA, 324.16 (2020), 1615 <https://doi.org/10.1001/jama.2020.18543>.
[21] Michael Barnett, ‘Embargoed Title’.
[22] Jie Yang and others, ‘Disparities in Outpatient Visits for Mental Health and/or Substance Use Disorders during the COVID Surge and Partial Reopening in Massachusetts’, General Hospital Psychiatry, 67 (2020), 100–106 <https://doi.org/10.1016/j.genhosppsych.2020.09.004>.
[23] Pooja A. Lagisetty and others, ‘Buprenorphine Treatment Divide by Race/Ethnicity and Payment’, JAMA Psychiatry, 76.9 (2019), 979 <https://doi.org/10.1001/jamapsychiatry.2019.0876>.
[24] Sarah E. Wakeman and others, ‘A Hospital-Wide Initiative to Redesign Substance Use Disorder Care: Impact on Pharmacotherapy Initiation’, Substance Abuse, 2020, 1–8 <https://doi.org/10.1080/08897077.2020.1846664>.
[25] Reps Paul Tonko and others, ‘The Mainstreaming Addiction Treatment (MAT) Act’, 1.
[26] Marc Auriacombe and others, ‘French Field Experience with Buprenorphine’, The American Journal on Addictions, 13 Suppl 1 (2004), S17-28 <https://doi.org/10.1080/10550490490440780>.
[27] tjordan_drupal, ‘CDC: Drug Overdose Deaths up 4.6% in 2019 | AHA News’ <https://www.aha.org/news/headline/2020-07-16-cdc-drug-overdose-deaths-46-2019> [accessed 8 December 2020].
28 The authors wish to thank Barbara Cunningham for copyediting this document.